a public good project by the
Synthesis
Company
of California

© 2026

Susanna A. McColley | doi.page

0 works0 citations0 h-index

Susanna A. McColley

Lurie Children's Hospital(US)Lurie Children's Hospital(US)Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Publications by Year

Research Areas

Cystic Fibrosis Research Advances, Neonatal Respiratory Health Research, Tracheal and airway disorders, Pediatric health and respiratory diseases, Neuroscience of respiration and sleep

Most-Cited Works

→ Lumacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508delCFTR(2015)1,609 cited
→ Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation(2017)911 cited
→ Inability of Clinical History to Distinguish Primary Snoring From Obstructive Sleep Apnea Syndrome in Children(1995)646 cited
→ A CFTR corrector (lumacaftor) and a CFTR potentiator (ivacaftor) for treatment of patients with cystic fibrosis who have a phe508del CFTR mutation: a phase 2 randomised controlled trial(2014)438 cited
→ Clinical Significance of Microbial Infection and Adaptation in Cystic Fibrosis(2011)400 cited
→ Respiratory Compromise After Adenotonsillectomy in Children With Obstructive Sleep Apnea(1992)356 cited

→ Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial(2014)334 cited

→ Efficacy and safety of lumacaftor and ivacaftor in patients aged 6–11 years with cystic fibrosis homozygous for F508del-CFTR : a randomised, placebo-controlled phase 3 trial(2017)293 cited

→ A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele(2021)272 cited

→ Ivacaftor treatment of cystic fibrosis in children aged 12 to <24 months and with a CFTR gating mutation (ARRIVAL): a phase 3 single-arm study(2018)265 cited